[go: up one dir, main page]

CY1122951T1 - Φαρμακευτικα σκευασματα ενος αναστολεα υδροξυλασης ηιf - Google Patents

Φαρμακευτικα σκευασματα ενος αναστολεα υδροξυλασης ηιf

Info

Publication number
CY1122951T1
CY1122951T1 CY20201100383T CY201100383T CY1122951T1 CY 1122951 T1 CY1122951 T1 CY 1122951T1 CY 20201100383 T CY20201100383 T CY 20201100383T CY 201100383 T CY201100383 T CY 201100383T CY 1122951 T1 CY1122951 T1 CY 1122951T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical formulations
hydroxylase inhibitor
hif hydroxylase
hif
inhibitor
Prior art date
Application number
CY20201100383T
Other languages
English (en)
Inventor
David CONCA
Lee Allen Flippin
Scott David LEIGH
Claudia WITSCHI
Lee Robert WRIGHT
Original Assignee
Fibrogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51063834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122951(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fibrogen, Inc. filed Critical Fibrogen, Inc.
Publication of CY1122951T1 publication Critical patent/CY1122951T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα αποκάλυψη αφορά σε φαρμακευτικά σκευάσματα [(4-υδροξυ-1-μεθυλο-7-φαινοξυ-ισοκινολινο-3-καρβονυλ) -αμινο] -οξικού οξέος και σε μεθόδους χρήσης τους.
CY20201100383T 2013-06-06 2020-04-27 Φαρμακευτικα σκευασματα ενος αναστολεα υδροξυλασης ηιf CY1122951T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361831909P 2013-06-06 2013-06-06
PCT/US2014/041021 WO2014197660A1 (en) 2013-06-06 2014-06-05 Pharmaceutical formulations of a hif hydroxylase inhibitor

Publications (1)

Publication Number Publication Date
CY1122951T1 true CY1122951T1 (el) 2021-10-29

Family

ID=51063834

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100383T CY1122951T1 (el) 2013-06-06 2020-04-27 Φαρμακευτικα σκευασματα ενος αναστολεα υδροξυλασης ηιf

Country Status (25)

Country Link
US (3) US20160120859A1 (el)
EP (2) EP3708154A1 (el)
JP (4) JP6604941B2 (el)
KR (3) KR102291860B1 (el)
CN (5) CN110448537A (el)
AU (1) AU2014274890B2 (el)
CA (1) CA2914049C (el)
CY (1) CY1122951T1 (el)
DK (1) DK3003284T3 (el)
ES (1) ES2786924T3 (el)
HK (1) HK1222550A1 (el)
HR (1) HRP20200615T1 (el)
HU (1) HUE049623T2 (el)
IL (3) IL298998B2 (el)
LT (1) LT3003284T (el)
ME (1) ME03777B (el)
MX (3) MX2015016536A (el)
PL (1) PL3003284T3 (el)
PT (1) PT3003284T (el)
RS (1) RS60464B1 (el)
SG (1) SG11201509764RA (el)
SI (1) SI3003284T1 (el)
SM (1) SMT202000190T1 (el)
WO (1) WO2014197660A1 (el)
ZA (1) ZA201508712B (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0411055B1 (pt) 2003-06-06 2018-08-21 Fibrogen, Inc Compostos de heteroarilas contendo nitrogênio. seus usos no aumento da eritropoietina endógena, composição farmacêutica que os compreende e método in vitro de inibição da atividade da enzima hidrolase
JP5649584B2 (ja) 2008-11-14 2015-01-07 フィブロジェン インコーポレイテッド Ｈｉｆヒドロキシラーゼ阻害剤としてのチオクロメン誘導体
KR20220164068A (ko) 2012-07-16 2022-12-12 피브로겐, 인크. 프롤릴 하이드록실라제 억제제 [(4-하이드록시-1-메틸-7-페녹시-아이소퀴놀린-3-카보닐)-아미노]-아세트산의 결정형
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
PL2872487T3 (pl) 2012-07-16 2017-09-29 Fibrogen, Inc. Sposób wytwarzania związków izochinolinowych
CN110448537A (zh) 2013-06-06 2019-11-15 菲布罗根有限公司 Hif羟化酶抑制剂的药物制剂
CN115607521A (zh) 2015-04-01 2023-01-17 阿克比治疗有限公司 用于治疗贫血的组合物和方法
WO2019042485A1 (en) 2017-08-30 2019-03-07 Zentiva, K.S. FORMS IN THE STRONG STATE OF ROXADUSTAT
JP7144510B2 (ja) * 2017-09-04 2022-09-29 サンド・アクチエンゲゼルシヤフト 経口投与可能なｈｉｆプロリルヒドロキシラーゼ阻害剤の共結晶
CN110664814A (zh) * 2019-10-24 2020-01-10 上海长海医院 Fg-4592在制备治疗炎性肠病药物中的用途
CN110934833B (zh) * 2019-12-17 2022-08-19 河北长天药业有限公司 一种复方氨酚那敏颗粒
TW202207930A (zh) * 2020-03-17 2022-03-01 印度商卡地拉保健有限公司 包含ｈｉｆ脯胺醯基羥化酶抑制劑之調和物
US20220280482A1 (en) * 2021-03-06 2022-09-08 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
CN114796280B (zh) * 2022-06-15 2024-06-25 河北长天药业有限公司 一种复方氨酚那敏颗粒及其制备工艺
EP4321155A1 (en) 2022-08-08 2024-02-14 Sanovel Ilac Sanayi Ve Ticaret A.S. An oral pharmaceutical composition comprising roxadustat
CN118436652A (zh) * 2024-04-18 2024-08-06 南方医科大学顺德医院(佛山市顺德区第一人民医院) 一种罗沙司他药物制剂及其应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2101421T3 (es) 1993-11-02 1997-07-01 Hoechst Ag Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
ES2686625T3 (es) 2001-12-06 2018-10-18 Fibrogen, Inc. Métodos para el tratamiento o prevención de la anemia
US8318703B2 (en) * 2001-12-06 2012-11-27 Fibrogen, Inc. Methods for improving kidney function
DE10209692A1 (de) 2002-03-06 2003-09-18 Merck Patent Gmbh Isochinolinderivate
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) * 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
JP4805234B2 (ja) * 2002-12-16 2011-11-02 キッセイ薬品工業株式会社 経口固形医薬
AU2003289320C1 (en) 2002-12-16 2018-09-06 Kissei Pharmaceutical Co., Ltd. Solid drug for oral use
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
BRPI0411055B1 (pt) 2003-06-06 2018-08-21 Fibrogen, Inc Compostos de heteroarilas contendo nitrogênio. seus usos no aumento da eritropoietina endógena, composição farmacêutica que os compreende e método in vitro de inibição da atividade da enzima hidrolase
EP1658074B1 (en) 2003-08-01 2012-11-07 Fibrogen, Inc. Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
US7718797B2 (en) 2004-03-16 2010-05-18 Asahi Kasei Pharma Corporation Fasudil-containing preparation and method of improving stability thereof
WO2006094292A2 (en) 2005-03-02 2006-09-08 Fibrogen, Inc. Thienopyridine compounds, and methods of use thereof
CA2610956A1 (en) 2005-06-06 2006-12-14 Fibrogen, Inc. Improved treatment for anemia using a hif-alpha stabilising agent
JP5410751B2 (ja) 2005-06-15 2014-02-05 ファイブローゲン、インコーポレーテッド がん治療のための化合物および方法
UA97349C2 (uk) 2005-09-08 2012-02-10 Х. Луннбэк А/С Стійкі тверді склади сертиндолу
UA92920C2 (ru) 2005-10-31 2010-12-27 Кова Ко., Лтд. Таблетка с насечкой, включающая питавастатин, и имеющая превосходную фотостабильность
GB0523810D0 (en) 2005-11-23 2006-01-04 Astrazeneca Ab Pharmaceutical compositions
CN101374815B (zh) 2006-01-27 2013-07-17 菲布罗根有限公司 使低氧诱导因子（hif）稳定的氰基异喹啉化合物
PL1818057T3 (pl) * 2006-02-09 2010-09-30 Teva Pharma Trwałe preparaty farmaceutyczne montelukastu sodu
JP2009528279A (ja) 2006-02-16 2009-08-06 ファイブローゲン、インコーポレーテッド 脳卒中を治療するための化合物および方法
MX2008012734A (es) 2006-04-04 2009-01-29 Fibrogen Inc Compuestos pirrolo- y tiazolo-piridina como moduladores del factor inducible de hipoxia (hif).
WO2007141743A2 (en) * 2006-06-06 2007-12-13 Ranbaxy Laboratories Limited A tablet dosage form comprising cetirizine and pseudoephedrine
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
JP5683058B2 (ja) 2007-04-27 2015-03-11 ニプロ株式会社 経口固形製剤及びその製造方法
JP2011500548A (ja) 2007-10-12 2011-01-06 アストラゼネカ アクチボラグ マンニトールおよび／または微結晶性セルロースを含むジボテンタン組成物
EP2222305A1 (en) 2007-11-02 2010-09-01 Fibrogen, Inc. Methods for reducing blood pressure
US8269008B2 (en) 2007-12-03 2012-09-18 Fibrogen, Inc. Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
EP2231157A1 (en) 2007-12-06 2010-09-29 Fibrogen, Inc. Methods for increasing endothelial progentior cells
US20110039879A1 (en) 2007-12-07 2011-02-17 FibroGen ,Inc. Methods for increasing white blood cells
EP2252619B1 (en) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
WO2009100250A1 (en) 2008-02-05 2009-08-13 Fibrogen, Inc. Chromene derivatives and use thereof as hif hydroxylase activity inhibitors
US8217043B2 (en) 2008-08-20 2012-07-10 Fibrogen, Inc. Compounds and methods for their use
WO2010024908A1 (en) 2008-08-26 2010-03-04 Fibrogen, Inc. Methods for treatment of multiple sclerosis
JP5649584B2 (ja) 2008-11-14 2015-01-07 フィブロジェン インコーポレイテッド Ｈｉｆヒドロキシラーゼ阻害剤としてのチオクロメン誘導体
US20100144737A1 (en) 2008-12-08 2010-06-10 Fibrogen, Inc. Methods for inhibiting t helper cell differentiation
CN106344533A (zh) 2009-01-29 2017-01-25 大日本住友制药株式会社 具有内核的口腔崩解片剂
JP2010248106A (ja) * 2009-04-14 2010-11-04 Dainippon Sumitomo Pharma Co Ltd フィルムコーティング錠
JP2012176899A (ja) 2009-05-19 2012-09-13 Mitsubishi Tanabe Pharma Corp ２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液
WO2012097331A1 (en) 2011-01-13 2012-07-19 Fibrogen, Inc. Methods for increasing reticulocyte hemoglobin content
CN103429240A (zh) 2011-01-13 2013-12-04 菲布罗根有限公司 增加平均红细胞体积的方法
EP2670750B1 (en) 2011-02-02 2016-09-14 Fibrogen, Inc. Naphthyridine derivatives as inhibitors of hypoxia inducible factor
AU2012289429B2 (en) 2011-07-22 2016-07-28 Beijing Betta Pharmaceuticals Co., Ltd Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
US20140309256A1 (en) 2011-11-09 2014-10-16 Fibrogen, Inc. Therapeutic Method
JP6129217B2 (ja) 2012-03-09 2017-05-17 フィブロジェン インコーポレイテッド Ｈｉｆヒドロキシラーゼインヒビターとしての４−ヒドロキシ−イソキノリン化合物
KR20220164068A (ko) 2012-07-16 2022-12-12 피브로겐, 인크. 프롤릴 하이드록실라제 억제제 [(4-하이드록시-1-메틸-7-페녹시-아이소퀴놀린-3-카보닐)-아미노]-아세트산의 결정형
PL2872487T3 (pl) 2012-07-16 2017-09-29 Fibrogen, Inc. Sposób wytwarzania związków izochinolinowych
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
ES2694297T3 (es) 2013-01-24 2018-12-19 Fibrogen, Inc. Formas cristalinas de ácido {[1-ciano-5-(4-clorofenoxi)-4-hidroxi-isoquinolina-3-carbonilo]-amino}-acético
CN110448537A (zh) 2013-06-06 2019-11-15 菲布罗根有限公司 Hif羟化酶抑制剂的药物制剂

Also Published As

Publication number Publication date
BR112015029693A8 (pt) 2019-12-24
PT3003284T (pt) 2020-08-10
IL296484A (en) 2022-11-01
US10765672B2 (en) 2020-09-08
RU2015151056A3 (el) 2018-05-03
WO2014197660A1 (en) 2014-12-11
RS60464B1 (sr) 2020-07-31
CN111728952A (zh) 2020-10-02
EP3003284B1 (en) 2020-02-12
US20190008846A1 (en) 2019-01-10
IL296484B1 (en) 2024-11-01
MX2020003096A (es) 2020-08-17
JP2019137703A (ja) 2019-08-22
EP3003284A1 (en) 2016-04-13
CN111728950A (zh) 2020-10-02
KR20210104173A (ko) 2021-08-24
AU2014274890A1 (en) 2015-12-17
SI3003284T1 (sl) 2020-08-31
RU2681304C2 (ru) 2019-03-06
CN110448537A (zh) 2019-11-15
IL242759B2 (en) 2023-05-01
ME03777B (me) 2021-04-20
CA2914049A1 (en) 2014-12-11
DK3003284T3 (da) 2020-03-30
HRP20200615T1 (hr) 2020-07-10
ZA201508712B (en) 2020-07-29
PL3003284T3 (pl) 2020-08-10
JP6604941B2 (ja) 2019-11-13
CN105377242A (zh) 2016-03-02
IL298998B2 (en) 2024-07-01
NZ754196A (en) 2021-06-25
SMT202000190T1 (it) 2020-05-08
IL298998B1 (en) 2024-03-01
JP2023068197A (ja) 2023-05-16
IL242759A (el) 2015-12-31
IL242759B1 (en) 2023-01-01
BR112015029693A2 (pt) 2017-07-25
KR102291860B1 (ko) 2021-08-20
MX2022011225A (es) 2022-10-07
KR20220164069A (ko) 2022-12-12
RU2015151056A (ru) 2017-07-14
IL296484B2 (en) 2025-03-01
JP6861758B2 (ja) 2021-04-21
JP2021100971A (ja) 2021-07-08
LT3003284T (lt) 2020-04-27
US20160120859A1 (en) 2016-05-05
AU2014274890B2 (en) 2019-10-03
NZ714554A (en) 2021-06-25
IL298998A (en) 2023-02-01
MX2015016536A (es) 2016-08-11
SG11201509764RA (en) 2015-12-30
CA2914049C (en) 2021-10-12
JP2016523846A (ja) 2016-08-12
KR20160018514A (ko) 2016-02-17
EP3708154A1 (en) 2020-09-16
CN111728951A (zh) 2020-10-02
HK1222550A1 (zh) 2017-07-07
US20220054474A1 (en) 2022-02-24
HUE049623T2 (hu) 2020-09-28
ES2786924T3 (es) 2020-10-14

Similar Documents

Publication Publication Date Title
CY1122951T1 (el) Φαρμακευτικα σκευασματα ενος αναστολεα υδροξυλασης ηιf
CY1125155T1 (el) Κρυσταλλικες μορφες αναστολεα προλυλο υδροξυλασης
CY1121736T1 (el) Άλατα aramchol
CY1120646T1 (el) Προγονικα κυτταρα μεσοδερμικης προελευσης
CY1120529T1 (el) Προφαρμακα φουμαρικων αλατων και η χρηση τους στην αγωγη ποικιλων νοσων
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
EA201691582A1 (ru) Новые фармацевтические препараты
EA201792613A1 (ru) Модуляторы cot и способы их применения
BR112015021521A2 (pt) anticorpos anti-crth2 e métodos para seu uso
EA201690667A1 (ru) Композиции, содержащие антитело к pdl1
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
CL2016001458A1 (es) Derivado de sulfonamida o sales de adición de ácido farmaceuticamente aceptables del mismo.
EA201591751A1 (ru) Трипептидные эпоксикетонные ингибиторы протеазы
CY1119151T1 (el) Ν-(4-(αζαϊνδαζολ-6-υλ)-φαινυλ)-σουλφοναμιδiα και η χρηση τους ως φαρμακα
AR095977A1 (es) Un procedimiento para aumentar la formación de ácido piroglutámico de una proteína
BR112015005369A2 (pt) inibidores de usp30 e métodos para sua utilização
EA202091397A1 (ru) Бензохинолоновые ингибиторы vmat2
EA201591931A1 (ru) Композиции оксабициклогептанов и оксабициклогептенов
MX2016011290A (es) Composiciones de ester de colina de acido lipoico y metodos de uso.
CL2019002733A1 (es) Formulaciones de clorhidrato del ácido 1-amino-1-ciclopropanocarboxílico.
EA201500245A1 (ru) Твердый фармацевтический препарат, который содержит левотироксин
EA201591259A1 (ru) Твёрдые формы производного хиназолина и их применение в качестве ингибитора braf
MX374618B (es) Ésteres sulfatados de ácidos oligohidroxicarboxílicos, y uso de los mismos.
UY34552A (es) Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparación, y las composiciones farmacéuticas que la contienen
EA201500941A1 (ru) Способы и композиции для модуляции гамма-глутамилового цикла